

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			Application Number	<b>10/520,771</b>	
			Filing Date	<b>December 5, 2005</b>	
			First Named Inventor	<b>Mohammad Reza MEHRABI</b>	
			Art Unit	<b>1614</b>	
			Examiner Name	<b>Timothy P. THOMAS</b>	
Sheet	<b>1</b>	of	<b>2</b>	Attorney Docket No.	<b>B47357</b>

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Document No. No. – Kind Code <sup>2</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Doc	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

  

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Doc	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup>				

<b>EXAMINER SIGNATURE</b>		<b>DATE CONSIDERED</b>	
---------------------------	--	------------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	10/520,771
				Filing Date	June 27, 2008
				First Named Inventor	Mohammad Reza MEHRABI
				Art Unit	1614
				Examiner Name	Timothy P. THOMAS
Sheet	2	of	2	Attorney Docket No.	B47357

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published	T <sup>2</sup>
		PACHER, ET AL. "Beneficial hemodynamic effects of prostaglandin E <sub>1</sub> infusion in catecholamine-dependent heart failure: Results of a prospective, randomized, controlled study"; Critical Care Medicine; July 1994; pp. 1984-1090; Vol. 22, No. 7; Williams & Wilkins; US	
		PACHER, ET AL. "Ambulatory vasodilator therapy in heart failure: systematic review of the literature and personal observational experience"; The European Journal of Heart Failure; The European Society of Cardiology; 1999; pp. 263-267; Elsevier	
		STANEK; "Pharmacologic Bridging With Prostaglandin E1 Before Heart Transplantation – A New Chance for an Old Drug"; Journal of Clinical and Basic Cardiology; 2002; pp. 171-177; Issue 2	
		BERGER, ET AL. "Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure"; The European Journal of Heart Failure; 2007; pp. 202-208; Vol. 9; Elsevier	
		HÜLSMANN, ET AL. "Hemodynamic And Neurohumoral Effects of Long-term Prostaglandin E <sub>1</sub> Infusions in Outpatients With Severe Congestive Heart Failure"; The Journal of Heart and Lung Transplantation; May 1997; pp. 556-562; Vol. 16, No. 5; International Society for Heart and Lung Transplantation	

<b>EXAMINER SIGNATURE</b>		<b>DATE CONSIDERED</b>	
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p><sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.</p>			